Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response.
Publication/Presentation Date
10-27-2020
Abstract
We conducted a prospective evaluation of cord blood (CB)-derived adoptive cell therapy, after salvage chemotherapy, for patients with advanced myeloid malignancies and poor prognosis. Previously, we reported safety, feasibility, and preliminary efficacy of this approach. We present updated results in 31 patients who received intensive chemotherapy followed by CB infusion and identify predictors of response. To enhance the antileukemic effect, we selected CB units (CBU) with shared inherited paternal antigens and/or noninherited maternal antigens with the recipients. Twenty-eight patients with acute myeloid leukemia (AML), 2 with myelodysplastic syndrome, and 1 in chronic myeloid leukemia myeloid blast crisis were enrolled; 9 had relapsed after allogeneic transplant. Response was defined as
Volume
4
Issue
20
First Page
5146
Last Page
5156
ISSN
2473-9537
Published In/Presented At
Chaekal, O. K., Scaradavou, A., Masson Frenet, E., Albano, M. S., Cushing, M., Desai, P., Dobrila, L., Gergis, U., Guarneri, D., Hsu, J. M., Lee, S., Mayer, S. A., Phillips, A. A., Orfali, N., Ritchie, E. K., Roboz, G. J., Romeo, C., Samuel, M. S., Shore, T., & van Besien, K. (2020). Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood advances, 4(20), 5146–5156. https://doi.org/10.1182/bloodadvances.2020002805
Disciplines
Medicine and Health Sciences
PubMedID
33091124
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article